Smoothened-activating lipids drive resistance to CDK4/6 inhibition in Hedgehog-associated medulloblastoma cells and preclinical models

Vikas Daggubati, … , Jeremy F. Reiter, David R. Raleigh

*J Clin Invest.* 2021;131(6):e141171. [https://doi.org/10.1172/JCI141171](https://doi.org/10.1172/JCI141171).

**Graphical abstract**

Find the latest version:

[https://jci.me/141171/pdf](https://jci.me/141171/pdf)
The Journal of Clinical Investigation

CONCISE COMMUNICATION

Introduction

Hedgehog (HH) signaling is essential for development and adult tissue homeostasis (1). Misactivation of the HH pathway is associated with congenital disorders and cancers, such as medulloblastoma and basal cell carcinoma, the most common cancer in the United States (2). Vertebrate HH signals are transduced through the primary cilium, an antenna that projects from the surface of most cells (3). Upon pathway activation, Smoothened (SMO) accumulates in the primary cilium and activates the GLI family of transcription factors, which travel to the nucleus and activate the HH gene expression program. SMO inhibition has improved the treatment of adult basal cell carcinoma (4) but has not improved the treatment of pediatric medulloblastoma because of acquired resistance (5, 6) and toxicity (7). Current therapies for medulloblastoma, such as cytotoxic chemotherapy and ionizing radiation, cause secondary cancers and permanent endocrine, neurologic, and cognitive dysfunctions (8, 9). Thus, there is an urgent, unmet need for new therapies to treat pediatric patients with medulloblastoma.

We have shown that CDK6, an enzyme critical for G1-phase progression through the cell cycle (10), is a direct transcriptional target of oncogenic HH signaling and that genetic or pharmacologic inhibition of CDK6 blocks the growth of HH-associated medulloblastomas (11). Small-molecule CDK4/6 inhibitors have revolutionized metastatic breast cancer treatment (10), and clinical trials exploring the efficacy of CDK4/6 inhibitors in medulloblastoma are underway (NCT04238819, NCT03434262, and NCT01878617). Nevertheless, acquired resistance to molecular monotherapy is common in medulloblastoma (5, 6) and breast cancer (10), suggesting that CDK4/6 inhibitors may be most effective in combination with other therapies that block resistance mechanisms, which remain unknown in medulloblastoma.

Results and Discussion

To identify the mechanisms underlying resistance to CDK4/6 inhibitors in HH-associated medulloblastoma, cellular and biochemical mechanisms of HH signal transduction were studied in DAOY, UW228, and ONS76 human medulloblastoma cells (12). Compared with DAOY cells, the majority of UW228 cells lacked primary cilia (Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/JCI141171DS1), and ONS76 cells expressed shortened cilia (Supplemental Figure 1B), a marker of reduced HH signal transduction (13–15). When stimulated with recombinant Sonic Hedgehog

Medulloblastoma is an aggressive pediatric brain tumor that can be driven by misactivation of the Hedgehog (HH) pathway. CDK6 is a critical effector of oncogenic HH signaling, but attempts to target the HH pathway in medulloblastoma have been encumbered by resistance to single-agent molecular therapy. We identified mechanisms of resistance to CDK6 inhibition in HH-associated medulloblastoma by performing orthogonal CRISPR and CRISPR interference screens in medulloblastoma cells treated with a CDK4/6 inhibitor and RNA-Seq of a mouse model of HH-associated medulloblastoma with genetic deletion of Cdk6. Our concordant in vitro and in vivo data revealed that decreased ribosomal protein expression underlies resistance to CDK6 inhibition in HH-associated medulloblastoma, leading to ER stress and activation of the unfolded protein response (UPR). These pathways increased the activity of enzymes producing Smoothened-activating (SMO-activating) sterol lipids that sustained oncogenic HH signaling in medulloblastoma despite cell-cycle attenuation. We consistently demonstrated that concurrent genetic deletion or pharmacological inhibition of CDK6 and HSD11b2, an enzyme producing SMO-activating lipids, additively blocked cancer growth in multiple mouse genetic models of HH-associated medulloblastoma. Our data reveal what we believe to be a novel pathway of resistance to CDK4/6 inhibition as well as a novel combination therapy to treat the most common malignant brain tumor in children.

Smootherned-activating lipids drive resistance to CDK4/6 inhibition in Hedgehog-associated medulloblastoma cells and preclinical models

Vikas Daggubati,1,2,3,4 Jordan Hochstelter,1,2 Anirudh Bommireddy,1,2 Abrar Choudhury,1,2,3,4 Alexis Leigh Krup,1 Pervinder Kaur,1 Pakteema Tong,1 Amy Li,1 Libin Xu,1 Jeremy F. Reiter,6 and David R. Raleigh1,2,3

1Department of Radiation Oncology, 2Department of Neurological Surgery, 3Biomedical Sciences Graduate Program, and 4Medical Scientist Training Program, UCSF, San Francisco, California, USA.

3Department of Medicinal Chemistry, University of Washington, Seattle, Washington, USA.

4Department of Biochemistry and Biophysics, Cardiovascular Research Institute, Chan Zuckerberg Biohub, UCSF, San Francisco, California, USA.

Conflict of interest: The authors have declared that no conflict of interest exists.

Copyright: © 2021, American Society for Clinical Investigation.

Submitted: June 8, 2020; Accepted: January 14, 2021; Published: March 15, 2021.

DAOY Cas9-KRAB cells, we targeted sgRNA enrichment between DAOY Cas9 or DAOYdCas9-KRAB cells treated to enrich for resistant clones (Figure 1B). Genes conferring resistance were suppressed in Math1-Cre/WT medulloblastoma (18, 19). Medulloblastomas were inhibited by the induction of CDK6 (10, 16, 17), but gene ontology (GO) analyses in DAOYdCas9-KRAB and 2 independent DAOYCas9 abamaciclib resistance screens identified enrichment of sgRNAs targeting ribosome and ribosome biogenesis genes (Figure 1C, Supplemental Figure 2, A and B, and Supplemental Table 1). CDK6 expression did not increase in genome-wide enrichment screens (Supplemental Figure 2C), or with conditioned resistance to abamaciclib in parental DAOY cells (Supplemental Figure 2D), suggesting that the resistance mechanisms previously reported in breast cancer were not present in our medulloblastoma samples. To validate these results in vitro, we transduced DAOYdCas9-KRAB cells with sgRNAs targeting the top 24 genes from our CRISPR interference (CRISPRi) abamaciclib resistance screen and performed clonogenic assays to confirm that stable suppression of these genes promoted resistance to CDK4/6 inhibition in HH-associated medulloblastoma cells (Supplemental Figure 3). To validate these results in vivo, we used a conditional mouse genetic model that relies on Cre recombinase under the control of Math1 regulatory sequences to express a constitutively active, oncogenic point mutation of Smo (SmoM2) in cerebellar external granule layer cells that give rise to HH-associated medulloblastoma (18, 19). Medulloblastomas were isolated from six Math1-Cre SmoM2<sup>Cdk6<sup>WT</sup>/WT</sup> mice for RNA-Seq and differential expression analysis compared with 3 Math1-Cre SmoM2<sup>Cdk6<sup>WT</sup>/WT</sup> medulloblastomas (ref. 11 and Supplemental Table 2). The majority of differentially expressed genes were suppressed with loss of Cdk6 (Supplemental Figure 4A), and, consistent with genome-wide resistance screens in vitro, GO analyses revealed that ribosome and ribosome biogenesis genes dominated suppressed transcripts in Math1-Cre SmoM2<sup>Cdk6<sup>WT</sup>/WT</sup> medulloblastomas compared with Math1-Cre SmoM2<sup>Cdk6<sup>WT</sup>/WT</sup> tumors (Supplemental Figure 4B and Supplemental Table 2).

Inactivating mutations in ribosome genes can drive cancer (20), and genome-wide screens demonstrate functional clustering of ribosome subunits (21), suggesting that loss of ribosome genes may have similar phenotypic consequences. Our in vitro and in vivo data converged on the suppression of RPL10 and RPL23A as drivers of resistance to CDK4/6 inhibition (Figure 1D and Supplemental Table 1), and RPL10 substitutions are found in approximately 10% of T cell acute lymphoblastic leukemias and multiple myelomas (22, 23). Thus, to validate the function of RPL10 in HH-associated medulloblastoma, we suppressed RPL10 expression in DAOY<sup>WT/Cas9-KRAB</sup> cells (Figure 1E). Clonogenic assays of stable cell lines treated with abamaciclib revealed that loss of RPL10 enhanced clonogenic growth compared with DAOY<sup>WT/Cas9-KRAB</sup> cells expressing sgNTCs (Figure 1F). Moreover, expression of RPL10 and other ribosome biogenesis genes was suppressed in Math1-Cre SmoM2<sup>Cdk6<sup>WT</sup>/WT</sup> medulloblastomas compared with expression in Math1-Cre SmoM2<sup>Cdk6<sup>WT</sup>/WT</sup> tumors (Figure 1G, Supplemental Figure 4C, and Supplemental Table 2).

Cellular functions of RPL10 are poorly understood (24), but ribosomes and ribosome biogenesis are critical for lipid homeostasis (25). Indeed, inhibition of ribosome biogenesis causes ER stress (26), which activates the unfolded protein response (UPR) and stimulates lipogenesis (27, 28). Our laboratory and others have shown that sterol and oxysterol lipids bind to SMO and activate the HH transcriptional program (29, 30). Thus, ribosome gene suppression may activate the UPR to increase cellular levels of SMO-activating lipids and drive resistance to CDK4/6 inhibition in HH-associated medulloblastomas. To test this hypothesis, ribosome biogenesis, UPR activation, and SMO-activating lipid levels were quantified in DAOY<sup>WT/Cas9-KRAB</sup> cells stably expressing sgRNAs targeting RPL10 or sgNTCs (Figure 1E). Quantitative reverse transcriptase PCR (qRT-PCR) revealed that suppression of RPL10 inhibited ribosome biogenesis, as measured by decreased expression of ribosome precursor rRNAs, and activated the UPR, as measured by splicing of the master transcription factor XBP1 (Figure 1H and ref. 27). Immunoblots demonstrated that suppression of RPL10 also increased phosphorylation of eIF2α and expression of ATF4 (Figure 1I), both of which are hallmarks of UPR activation (31). Immunofluorescence confocal microscopy using perfringolysin O (PFO), a bacterial toxin that labels the SMO agonist cholesterol in live cells (29), further showed that suppression of RPL10 increased SMO-activating lipid levels in HH-associated medulloblastoma cells (Figure 1J and K).

The UPR activates parallel signaling pathways to coordinate diverse cellular responses, including Ire1 activation and XBP1 splicing; and PERK activation of eIF2α, phosphorylated eIF2α (p-eIF2α), and ATF4 (32). Suppression of ribosome and ribosome biogenesis activated Ire-1/XBP1 and PERK signaling in HH-associated medulloblastoma cells (Figure 1, H and I), and Ire-1/XBP1 signaling is canonically associated with UPR-mediated lipogenesis (32). Thus, to define the biochemical mechanisms that increase SMO-activating lipids in HH-associated medulloblastoma cells after loss of ribosome genes, we treated DAOY<sup>WT/Cas9-KRAB</sup> cells stably expressing sgNTCs or sgRNAs suppressing RPL10 with the Ire-1 inhibitor KIRA6, the PERK inhibitor GSK2606414, or vehicle control. Immunofluorescence confocal microscopy using PFO showed that pharmacologic inhibition of Ire-1/XBP1 signaling blocked SMO-activating lipid induction in response to RPL10 suppression (Figure 1L) but that pharmacologic inhibition of PERK did not (Supplemental Figure 5A).
Figure 1. Suppression of ribosome biogenesis drives resistance to CDK4/6 inhibition in HH-associated medulloblastoma by inducing SMO-activating lipid synthesis. (A) Schematic of CRISPR and CRISPRi gene suppression through dsDNA breaks and steric inhibition, respectively. (B) Genome-wide CDK4/6 inhibition resistance screen study design for HH-associated medulloblastoma cells. GPP, Genetic Perturbation Platform; hCRISPRi, human CRISPRi. (C) Suppressed pathways in DAOY\textsuperscript{Cas9} (n = 2) and DAOY\textsuperscript{dCas9-KRAB} (n = 1) genome-wide CDK4/6 inhibition resistance screens. (D) Venn diagram of suppressed ribosome and ribosome biogenesis genes mediating the resistance to loss of CDK6 in HH-associated medulloblastoma in vitro and in vivo. Numbers indicate overlapping genes. Among these, only RPL10 and RPL23A were implicated in both in vitro and in vivo experiments. Non-ribosome genes were omitted from this analysis. (E) qRT-PCR assessment of RPL10 suppression in DAOY\textsuperscript{Cas9} cells. *P < 0.0001. n = 2. (F) DAOY\textsuperscript{Cas9} clonogenic assays after 10 days of abemaciclib treatment demonstrated that RPL10 suppression conferred resistance to CDK4/6 inhibition. *P = 0.0009. n = 2. (G) RNA-Seq differential expression analysis of mouse medulloblastomas. *P < 0.0001. n = 9. (H) qRT-PCR assessment of ribosome precursor rRNAs and the ratio of spliced XBP1 to unspliced XBP1 in DAOY\textsuperscript{Cas9} cells. *P = 0.008, **P = 0.006, and ***P < 0.0001. n = 3. (I) Immunoblot assessment of UPR activation through phosphorylation of eIF2α and induction of ATF4 in DAOY\textsuperscript{Cas9} cells. (J) Microscopic images of PFO cholesterol (white) and DNA (blue) staining in DAOY\textsuperscript{Cas9} cells. Scale bar: 100 μm. (K) PFO cholesterol staining and quantification in DAOY\textsuperscript{Cas9} cells. *P < 0.0001. n = 2, with more than 40 cells counted per experiment. (L) PFO cholesterol staining and quantification in DAOY\textsuperscript{Cas9} cells after treatment with KIRA6, a UPR inhibitor that blocks IRE-1 upstream of lipogenic signaling. *P < 0.0001. n = 2, with more than 40 cells counted per experiment. (M) Lipidomic mass spectrometry for SMO-activating lipids and precursor lipids (7k-C) in DAOY\textsuperscript{Cas9} cells. *P = 0.0017, **P < 0.0001, ***P = 0.0091, and ****P = 0.0015. Data are shown as the mean ± SEM. A Student’s t test was used for statistical comparisons. n = 3.

To determine whether loss of other ribosome genes induced the UPR or SMO-activating lipids, we transduced DAOY\textsuperscript{Cas9-KRAB} cells with sgRNAs suppressing RPL23A (Supplemental Figure 5B), which activated the UPR (Supplemental Figure 5C) and increased SMO-activating lipid levels (Supplemental Figure 5D). Ribosomes fulfill essential but semiredundant cellular functions (21), and in contrast to RPL10 suppression, RPL23A suppression decreased DAOY viability (Supplemental Figure 5E), which prevented the functional assessment of resistance to CDK4/6 inhibitors. RPL10 and RPL23A suppression also decreased UW228 and ONS76 viability (Supplemental Figure 5F) and activated the UPR in ONS76 cells but not UW228 cells (Supplemental Figure 5, G–L). Although
abemaciclib blocked clonogenic growth of UW228 and ONS76 cells in a dose-dependent manner (Supplemental Figure 5, I and L), our findings that these cells lacked mechanisms underlying ciliary HH signal transduction and the UPR underscore the suboptimal nature of UW228 and ONS76 cells for studying oncogenic ciliary HH signaling. In support of this hypothesis, DAOYdCas9-KRAB suppression of RPL27A, which was implicated in resistance to CDK4/6 inhibitors in vitro (Supplemental Table 1), did not impair cell viability and validated that loss of other ribosome genes can mediate resistance to cell-cycle inhibition in HH-associated medulloblastoma cells (Supplemental Figure 5, M and N). In sum, these data corroborate the essential, context-dependent cellular functions of ribosome genes (32) and reveal that ribosome suppression can confer a growth advantage in the context of cell-cycle inhibition in HH-associated medulloblastoma.

To identify enzymes producing SMO-activating lipids that are influenced by ribosome gene expression and the UPR, we analyzed DAOYdCas9-KRAB cells stably expressing sgRNAs targeting RPL10 or sgNTCs by lipidomic mass spectrometry. Suppression of RPL10 increased cellular levels of cholesterol and 7-ketocholesterol (7k-C) (Figure 1M), which are produced by DHCR7 and HSD11β2, respectively (33). DHCR7 promotes HH pathway activity by producing cholesterol (29), and we have shown that HSD11β2 drives HH-associated medulloblastoma by producing SMO-activating oxysterols (30). Suppression of RPL10 also increased 7k,27-dihydroxycholesterol (7k,27-OHC) and 7,27-dihydroxycholesterol (7,27-DHC) (Figure 1M), both of which are byproducts of 7k-C, produced by HSD11β2, that bind to SMO and activate the HH pathway (30). Stable transduction of DAOY Cas9 and DAOYdCas9-KRAB cells with sgRNAs targeting HSD11B2 demonstrated that genetic inactivation or suppression of HSD11B2 inhibited the HH transcriptional program and attenuated clonogenic growth of HH-associated medulloblastoma cells compared with cells transduced with sgNTCs (Supplemental Figure 6). However, immunoblots revealed that suppression of RPL10 in DAOYdCas9-KRAB cells did not increase the expression of DHCR7 or HSD11β2 proteins (Supplemental Figure 7A), and RNA-Seq of genetically engineered mouse models showed that enzyme transcripts were not increased in HH-associated medulloblastomas lacking Cdk6 (Supplemental Figure 7B). These data suggest that the UPR regulates the activity, but not expression, of enzymes producing SMO-activating lipids, which has been demonstrated for other lipid synthases that are stimulated by UPR-mediated changes in ER membrane composition (34). Indeed, ER stress is known to activate lipogenesis through the UPR, which provides lipids for ER expansion that serve as precursors for lipid synthases localizing to the ER (35). In support of this hypothesis, 7-dehydroxycholesterol, which DHCR7 converts into cholesterol, was also increased in DAOYdCas9-KRAB cells stably expressing sgRNAs suppressing RPL10 compared with sgNTCs (Supplemental Figure 7C).
Our discovery that SMO-activating lipid levels can increase in response to CDK4/6 inhibition suggests that combination molecular therapy against CDK6 and HSD11B2 may be an effective treatment for HH-associated medulloblastomas. To test this hypothesis, we treated Math1-Cre SmoM2C mice with (a) vehicle control, (b) abemaciclib, (c) the HSD11B2 inhibitor carbenoxolone (CNX) that penetrates the blood-brain barrier (30, 36), or (d) both abemaciclib and CNX. Combination molecular therapy reduced the histologic prevalence of malignant small, round blue cells that are characteristic of medulloblastoma and partially restored the internal architecture of cerebella when compared with vehicle control or molecular monotherapy (Figure 2A). Moreover, Math1-Cre SmoM2C medulloblastomas treated with combination molecular therapy showed a significant reduction in tumor weight compared with vehicle control or monotherapy (Figure 2B). CNX in combination with palbociclib, another small-molecule CDK4/6 inhibitor, was also more effective than monotherapy at blocking the growth of medulloblastomas in the Math1-Cre Ptc1C/C conditional mouse genetic model of HH-associated medulloblastoma (Figure 2, C and D). To validate the specificity of our results, Math1-Cre, SmoM2C, Cdk6lox, and Hsd11b2lox alleles were combined, and mice were monitored for survival from medulloblastomas expressing Cdk6, Hsd11b2, both, or neither (Figure 2E and Supplemental Figure 7). We previously reported that genetic inhibition of Hsd11b2 decreases SMO-activating lipid levels, HH signaling, and growth of HH-associated medulloblastoma in mice (30). Consistently, combined heterozygous genetic deletion of Cdk6 and Hsd11b2 modestly increased the length of survival from Math1-Cre SmoM2C medulloblastomas (median survival, 64 ± 16 days vs. 56 ± 3 days, P = 0.006), and homozygous genetic deletion of Cdk6 and Hsd11b2 doubled the length of survival (median survival, 113 ± 22 days, P = 7 × 10−9), resulting in durable cures for 27% of mice versus 0% of mice with intact or heterogeneous loss of Cdk6 or Hsd11b2 (Figure 2E and Supplemental Figure 8).

In conclusion, SMO-activating lipids underlie resistance to CDK4/6 inhibition in HH-associated medulloblastoma, establishing a preclinical rationale for the use of combination molecular therapy to treat the most common malignant brain tumor in children. Our results reveal that pharmacologic inhibition of the cell cycle can be overcome by suppression of ribosomes or ribo-some biogenesis genes, which activates the UPR to stimulate enzymes producing sterol and oxysterol lipids that activate SMO and sustain oncogenic HH signaling. As a proof of principle, we demonstrate that genetic or pharmacologic inhibition of HSD11B2 can enhance the efficacy of cell-cycle inhibitors for HH-associated medulloblastoma, but it is possible that inhibition of other enzymes producing SMO-activating lipids may also provide a benefit to patients with HH-associated medulloblastomas. Suppression of ribosome biogenesis has not been identified as a mechanism of resistance to cell-cycle inhibition in other cancers (37–39). Given the broad metabolic functions of ribosomes (20), including promotion of breast cancer metastasis (40), lipid homeostasis may influence resistance to pharmacologic inhibitors of the cell cycle in breast or other cancers.

Methods

Refer to the Supplemental Methods for details.

Data availability. All raw sequencing data can be accessed in the NCBI’s Gene Expression Omnibus (GEO) database (GEO GSE164311).

Study approval. All animal protocols and experimental protocols were approved by the IACUC of UCSF (AN174769-02).

Author contributions

VD and DRR designed the study and analysis. Experiments were performed by VD, JH, AB, AC, ALK, PK, PT, AL, and DRR. Data analysis was performed by VD, JH, AB, AC, PT, AL, and DRR. The study was supervised by LX, JFR, and DRR. The manuscript was prepared by VD and DRR with input from all authors.

Acknowledgments

The authors thank S. John Liu, Harish N. Vasudevan, Rajat Rohatgi, Luke Gilbert, Davide Ruggero, Till Milde, and Jonathan Weissman for providing reagents and expertise. This study was supported by a St. Baldrick’s Sumer Fellowship (to VD); NIH grant RO1 HD092659 (to LX); NIH grant T32 GM007618 (to VD and AC); and the UCSF Physician Scientist Scholar Program and NIH grant K08 CA212279 (to DRR). Graphical abstract illustration credit: Noel Sirivansanti.

Address correspondence to: David R. Raleigh, UCSF Helen Diller Cancer Research Building, 1450 3rd Street, HD481, San Francisco, California 94158, USA. Phone: 415.353.7175; Email: david.raleigh@ucsf.edu.

16. Li Z, et al. Loss of the FAT1 tumor suppressor...